奈达铂注射剂联合多西他赛注射液治疗晚期非小细胞肺癌的预后分析  

Prognostic Analysis of Nedaplatin Injection Combined with Docetaxel Injection in the Treatment of Advanced Non-small Cell Lung Cancer

作　　者：巴艳华[1] 刘兴安[1] 王琳[1] 侯继院[1] 单国用[1] BA Yanhua;WANG Lin(Zhengzhou People's Hospital,Zhengzhou,450003)

机构地区：[1]郑州人民医院

出　　处：《实用癌症杂志》2019年第7期1168-1171,共4页The Practical Journal of Cancer

基　　金：国家自然科学基金项目(编号:81373879)

摘　　要：目的探讨奈达铂注射剂联合多西他赛注射液治疗晚期非小细胞肺癌(NSCLC)的预后。方法选取晚期NSCLC患者100例,依据随机数字表法分为A组和B组,每组50例,A组给予顺铂联合多西他赛注射液治疗,B组给予奈达铂注射剂联合多西他赛注射液治疗,比较两组治疗疗效及预后。结果 A组和B组治疗后血清可溶性白介素2受体(SIL-2R)、糖类抗原199(CA19-9)、血管内皮生长因子(VEGF)明显低于治疗前,B组治疗后血清SIL-2R、CA19-9、VEGF明显低于A组,差异有统计学意义(P <0. 05);B组治疗有效率明显优于A组,差异有统计学意义(P <0. 05);B组不良反应发生率明显低于A组,差异有统计学意义(P <0. 05);随访3年期间,B组生存率、无进展生存时间、平均生存时间明显高于A组,差异有统计学意义(P <0. 05)。结论奈达铂注射剂联合多西他赛注射液治疗可有效提高NSCLC患者的治疗疗效,有利于改善患者的生存预后,且具有更良好的安全性,值得临床作进一步推广。Objective To discuss the prognostic analysis of nedaplatin injection combined with Docetaxel Injection in the treatment of advanced non-small cell lung cancer( NSCLC). Methods 100 patients with NSCLC were selected,according to the random distribution,all patients were divided into A group( 50 cases) and B group( 50 cases),A group was treated with cisplatin combined with Docetaxel Injection,B group was treated with nedaplatin injection combined with Docetaxel Injection. Comparison of the curative effect and prognosis of the 2 groups. Results The after treatmen of serum soluble interleukin 2 receptor( SIL-2 R),carbohydrate antigen 199( CA19-9) and vascular endothelial growth factor( VEGF) of A group and B group were significantly lower than those before treatment,the after treatmen of serum SIL-2 R、CA19-9、VEGF of B group was significantly lower than that A group,the difference was statistically significant( P < 0. 05). The effective rate of treatment in B group was significantly higher than that of A group,the difference was statistically significant( P < 0. 05). The incidence of adverse reaction in B group was significantly lower than that of A group,the difference was statistically significant( P < 0. 05). The follow-up period was3 years,survival rate,progression free survival time and average survival time in B group were significantly higher than those in A group,the difference was statistically significant( P < 0. 05). Conclusion Nedaplatin injection combined with Docetaxel Injection can effectively improve the therapeutic efficacy of NSCLC patients. It is beneficial to improve the survival and prognosis of patients,and has better safety,it’s worth for further clinical promotion.

关 键 词：奈达铂 多西他赛 晚期 非小细胞肺癌 预后 

分 类 号：R734.2[医药卫生—肿瘤]